- ►diabetesjournals.org G Boden, C Homko, M Mozzoli, M Zhang, K … - Diabetes, 2007 - Am Diabetes Assoc Elevated plasma free fatty acid (FFA) levels are responsible for much of the
insulin resistance in obese patients with type 2 diabetes. To lower plasma FFA
levels effectively and long term, we have treated eight obese patients with ... Cited by 19 - Related articles - BL Direct - All 11 versions
[CITATION] Comment on: Boden et al.(2007) Combined use of rosiglitazone and fenofibrate in patients …
JS Stroup - Am Diabetes Assoc I read with interest the article by Boden et al. (1) regarding the prevention of
fluid retention with the use of fenofibrate in combination with rosiglitazone.
Impressive clinical data has recently been published on the use of ... Cited by 1 - Related articles
[CITATION] PPARα and human metabolic disease
RK Semple, VKK Chatterjee, SO'Rahilly - Journal of Clinical Investigation, 2006 Cited by 2 - Related articles
JA Pasco, MJ Henry, GC Nicholson - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 3 - Related articles - BL Direct - All 3 versions
- ►fasebj.org [PDF] KB Sotiropoulos, A Clermont, Y Yasuda, C … - The FASEB Journal, 2006 - FASEB In this study, we investigated the underlying mechanisms that cause the serious
adverse effects of PPAR agonists (rosiglitazone, RSG)—edema and wt gain—in
models of diabetes and insulin resistance with the following aims: 1. To ... Cited by 29 - Related articles - BL Direct - All 4 versions
MF Magee, WL Isley - The American Journal of Cardiology, 2006 - Elsevier A major therapeutic question in considering accelerated atherogenesis in
patients with type 2 diabetes mellitus is whether reducing insulin resistance,
as a proximal defect of a host of proatherogenic abnormalities including ... Cited by 18 - Related articles - All 3 versions
- ►endojournals.org L Hansen, CT Ekstrom, R Tabanera y … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Activation of peroxisome proliferator-activated receptors (PPARs)- by
thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPAR / agonists
(pargluva, ragaglitazar) is a widely used pharmacological principle to ... Cited by 18 - Related articles - BL Direct - All 2 versions
- ►asnjournals.org J Karalliedde, R Buckingham, M Starkie, D … - Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol The efficacy of diuretics in the management of rosiglitazone (RSG)-induced fluid
retention was evaluated in a multicenter, randomized, open-label,
parallel-group, proof-of-concept study. Of 381 patients who had type 2 ... Cited by 39 - Related articles - BL Direct - All 5 versions
